The miR-34 family in cancer and apoptosis

Hollstein M, Sidransky D, Vogelstein B and Harris CC . p53 mutations in human cancers. Science 1991; 253: 49–53.

Soussi T . p53 alterations in human cancer: more questions than answers. Oncogene 2007; 26: 2145–2156.

Vogelstein B, Lane D and Levine AJ . Surfing the p53 network. Nature 2000; 408: 307–310.

Oren M . Decision making by p53: life, death and cancer. Cell Death Differ 2003; 10: 431–442.

Vousden KH and Lane DP . p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275–283.

Riley T, Sontag E, Chen P and Levine A . Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402–412.

Aylon Y and Oren M . Living with p53, dying of p53. Cell 2007; 130: 597–600.

el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R and Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825.

Yu J, Zhang L, Hwang PM, Kinzler KW and Vogelstein B . PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7: 673–682.

Hermeking H, Lengauer C, Polyak K, He TC, Zhang L and Thiagalingam S et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3–11.

Spurgers KB, Gold DL, Coombes KR, Bohnenstiehl NL, Mullins B and Meyn RE et al. Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem 2006; 281: 25134–25142.

Ho J and Benchimol S . Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 2003; 10: 404–408.

Lohr K, Moritz C, Contente A and Dobbelstein M . p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem 2003; 278: 32507–32516.

Budhram-Mahadeo V, Morris PJ, Smith MD, Midgley CA, Boxer LM and Latchman DS . p53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor. J Biol Chem 1999; 274: 15237–15244.

Valencia-Sanchez MA, Liu J, Hannon GJ and Parker R . Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006; 20: 515–524.

Peters L and Meister G . Argonaute proteins: mediators of RNA silencing. Mol Cell 2007; 26: 611–623.

Chen K and Rajewsky N . The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 2007; 8: 93–103.

Kloosterman WP and Plasterk RH . The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11: 441–450.

Bartel DP . MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215–233.

Meister G and Tuschl T . Mechanisms of gene silencing by double-stranded RNA. Nature 2004; 431: 343–349.

Pillai RS, Bhattacharyya SN and Filipowicz W . Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 2007; 17: 118–126.

Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM and Castle J et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769–773.

Garzon R, Fabbri M, Cimmino A, Calin GA and Croce CM . MicroRNA expression and function in cancer. Trends Mol Med 2006; 12: 580–587.

Cummins JM and Velculescu VE . Implications of micro-RNA profiling for cancer diagnosis. Oncogene 2006; 25: 6220–6227.

Esquela-Kerscher A and Slack FJ . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259–269.

Calin GA and Croce CM . MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857–866.

Lee YS and Dutta A . MicroRNAs in cancer. Annu Rev Pathol 2009; 4: 199–227.

Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R and Cheng A et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635–647.

Mayr C, Hemann MT and Bartel DP . Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007; 315: 1576–1579.

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K and Yi M et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189–198.

Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M and Lee KH et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745–752.

He L, He X, Lim LP, de Stanchina E, Xuan Z and Liang Y et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130–1134.

Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N and Moskovits N et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26: 731–743.

Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A and Menssen A et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6: 1586–1593.

Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R and Love RE et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17: 1298–1307.

Corney DC, Flesken-Nikitin A, Godwin AK, Wang W and Nikitin AY . MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007; 67: 8433–8438.

Hermeking H . p53 enters the microRNA world. Cancer Cell 2007; 12: 414–418.

Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T and Korner H et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591–2600.

Collado M, Blasco MA and Serrano M . Cellular senescence in cancer and aging. Cell 2007; 130: 223–233.

Welch C, Chen Y and Stallings RL . MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26: 5017–5022.

Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ and Brodeur GM et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 2008; 6: 735–742.

Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y and Nozawa Y et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008; 377: 114–119.

Ji Q, Hao X, Meng Y, Zhang M, Desano J and Fan D et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8: 266.

Sun F, Fu H, Liu Q, Tie Y, Zhu J and Xing R et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 2008; 582: 1564–1568.

Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K and Shinomura Y et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008; 68: 4123–4132.

Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M and Blanco D et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008; 105: 13556–13561.

Pigazzi M, Manara E, Baron E and Basso G . miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia. Cancer Res 2009; 69: 2471–2478.

Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB . Prediction of mammalian microRNA targets. Cell 2003; 115: 787–798.

Tazawa H, Tsuchiya N, Izumiya M and Nakagama H . Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 2007; 104: 15472–15477.

Li N, Fu H, Tie Y, Hu Z, Kong W and Wu Y et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 2009; 275: 44–53.

Yan D, Zhou X, Chen X, Hu DN, Dong XD and Wang J et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci 2009; 50: 1559–1565.

Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L and Eramo A et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res 2008; 68: 10128–10136.

Leucci E, Cocco M, Onnis A, De Falco G, van Cleef P and Bellan C et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol 2008; 216: 440–450.

Kong YW, Cannell IG, de Moor CH, Hill K, Garside PG and Hamilton TL et al. The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target gene. Proc Natl Acad Sci USA 2008; 105: 8866–8871.

Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT and Tsang P et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008; 27: 5204–5213.

Yamakuchi M, Ferlito M and Lowenstein CJ . miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105: 13421–13426.

Markey M and Berberich SJ . Full-length hdmX transcripts decrease following genotoxic stress. Oncogene 2008; 27: 6657–6666.

Leung AK and Sharp PA . microRNAs: a safeguard against turmoil? Cell 2007; 130: 581–585.

Cohen SM, Brennecke J and Stark A . Denoising feedback loops by thresholding—a new role for microRNAs. Genes Dev 2006; 20: 2769–2772.

Kozaki K, Imoto I, Mogi S, Omura K and Inazawa J . Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008; 68: 2094–2105.

Tryndyak VP, Ross SA, Beland FA and Pogribny IP . Down-regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocarcinogenesis induced by a methyl-deficient diet. Mol Carcinog 2008; [E-pub ahead of print]. doi: 10.1002/mc.20484.

Brooks CL and Gu W . How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 2009; 9: 123–128.

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J and Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834–838.

Zenz T, Mohr J, Eldering E, Kater AP, Buhler A and Kienle D et al. MiR-34a as part of the chemotherapy resistance network in chronic lymphocytic leukemia. Blood 2009; 113: 3801–3808.

Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B and Malcikova J et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 2009; [E-pub ahead of print]. doi: 10.1038.

Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T and Appella E et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 2008; 68: 3193–3203.

de Fougerolles A, Vornlocher HP, Maraganore J and Lieberman J . Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007; 6: 443–453.